MCID: OVR106
MIFTS: 44

Ovarian Clear Cell Carcinoma

Categories: Endocrine diseases, Reproductive diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Ovarian Clear Cell Carcinoma

MalaCards integrated aliases for Ovarian Clear Cell Carcinoma:

Name: Ovarian Clear Cell Carcinoma 12 15
Clear-Cell Ovarian Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050934

Summaries for Ovarian Clear Cell Carcinoma

Disease Ontology : 12 An ovarian carcinoma that has material basis in cells with clear cytoplasm and glycogen secreting hob nail cells.

MalaCards based summary : Ovarian Clear Cell Carcinoma, also known as clear-cell ovarian carcinoma, is related to endometrioid ovary carcinoma and endometriosis of ovary. An important gene associated with Ovarian Clear Cell Carcinoma is ARID1A (AT-Rich Interaction Domain 1A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Glioma. The drugs Sunitinib and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and monocytes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Clear cell ovarian carcinoma is one of several subtypes of ovarian carcinoma. The two types of ovarian... more...

Related Diseases for Ovarian Clear Cell Carcinoma

Diseases in the Ovarian Clear Cell Carcinoma family:

Ovarian Small Cell Carcinoma

Diseases related to Ovarian Clear Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 136)
# Related Disease Score Top Affiliating Genes
1 endometrioid ovary carcinoma 30.6 ARID1A PPP2R1A
2 endometriosis of ovary 30.5 ARID1A HNF1B
3 clear cell adenofibroma 30.4 ARID1A KRT7 PIK3CA
4 ovarian cancer 1 29.1 ARID1A HNF1B KRAS KRT7 PIK3CA TP53
5 adult hepatocellular carcinoma 10.7 PIK3CA TP53
6 breast squamous cell carcinoma 10.6 PIK3CA TP53
7 anal squamous cell carcinoma 10.6 PIK3CA TP53
8 papillary adenoma 10.6 KRT7 NAPSA
9 eccrine sweat gland neoplasm 10.6 KRT7 TP53
10 thymus adenocarcinoma 10.6 KRT7 NAPSA
11 ovarian clear cell adenocarcinoma 10.6 ARID1A HNF1B PIK3CA
12 bladder carcinoma in situ 10.6 KRT7 TP53
13 hidradenoma 10.6 KRT7 PIK3CA
14 papillary serous adenocarcinoma 10.6 KRT7 TP53
15 spiradenoma 10.6 KRT7 TP53
16 apocrine adenoma 10.5 KRAS PIK3CA
17 glycogen-rich clear cell breast carcinoma 10.5 KRT7 TP53
18 lichen sclerosus 10.5 CD44 TP53
19 aggressive digital papillary adenocarcinoma 10.5 KRAS PIK3CA
20 testicular malignant germ cell cancer 10.5 GPC3 NAPSA
21 gastric adenosquamous carcinoma 10.5 CD44 TP53
22 krukenberg carcinoma 10.4 HNF1B KRT7 NAPSA
23 hyperplastic polyposis syndrome 10.4 KRAS TP53
24 thyroid hurthle cell adenoma 10.4 PIK3CA PTEN
25 mutyh-associated polyposis 10.4 KRAS TP53
26 breast adenomyoepithelioma 10.4 KRT7 PIK3CA
27 pleomorphic carcinoma 10.4 KRT7 TP53
28 malignant spiradenoma 10.4 KRT7 PIK3CA TP53
29 ovarian benign neoplasm 10.4 KRT7 NAPSA ZNF217
30 breast myoepithelial neoplasm 10.4 KRT7 PIK3CA
31 bronchiolo-alveolar adenocarcinoma 10.4 KRAS KRT7
32 undifferentiated pleomorphic sarcoma 10.4 KRAS PIK3CA
33 ovary serous adenocarcinoma 10.4 KRAS ZNF217
34 endometriosis 10.3
35 mature teratoma 10.3 KRAS TP53
36 bile duct carcinoma 10.3 KRT7 PIK3CA TP53
37 anal canal adenocarcinoma 10.3 KRAS KRT7
38 ovarian cystadenocarcinoma 10.3 KRAS ZNF217
39 lung adenoid cystic carcinoma 10.3 KRAS PIK3CA
40 omodysplasia 10.3 CD44 GPC3
41 seminal vesicle tumor 10.3 GPC3 KRT7
42 uterine body mixed cancer 10.3 ARID1A PPP2R1A TP53
43 synchronous bilateral breast carcinoma 10.3 PTEN TP53
44 nevus, epidermal 10.3 KRAS PIK3CA
45 pulmonary blastoma 10.2 KRAS TP53
46 serous cystadenocarcinoma 10.2 PIK3CA PPP2R1A TP53
47 ampulla of vater neoplasm 10.2 KRAS KRT7
48 corneal abscess 10.2 KRT7 PTEN
49 rare adenocarcinoma of the breast 10.2 KRAS PIK3CA TP53
50 hypomagnesemia 2, renal 10.2 FXYD2 HNF1B

Graphical network of the top 20 diseases related to Ovarian Clear Cell Carcinoma:



Diseases related to Ovarian Clear Cell Carcinoma

Symptoms & Phenotypes for Ovarian Clear Cell Carcinoma

GenomeRNAi Phenotypes related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.5 ZNF217 FXYD2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 10.5 FXYD2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.5 KRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.5 HNF1B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.5 KRAS
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.5 ZNF217
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 10.5 HNF1B
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 10.5 ZNF217
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.5 KRAS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-167 10.5 HNF1B
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.5 ZNF217 FXYD2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 10.5 HNF1B
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.5 ZNF217
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.5 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 10.5 NAPSA
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.5 ZNF217 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.5 KRAS FXYD2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.5 NAPSA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.5 HNF1B KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.5 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.5 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.5 NAPSA
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.5 PTEN KRAS NAPSA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.5 HNF1B
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 10.5 FXYD2
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.5 NAPSA HNF1B ZNF217 FXYD2
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.5 PTEN ZNF217
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.5 FXYD2
29 Decreased viability in esophageal squamous lineage GR00235-A 9.56 PIK3CA PTEN HNF1B KRAS TP53 KRT7
30 Increased cell death HMECs cells GR00103-A-0 9.02 PIK3CA PPP2R1A PTEN TP53 ZNF217

MGI Mouse Phenotypes related to Ovarian Clear Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 CD44 KRT7 PIK3CA GPC3 PPP2R1A HNF1B
2 growth/size/body region MP:0005378 10.09 CD44 PIK3CA GPC3 PPP2R1A HNF1B ARID1A
3 embryo MP:0005380 10.02 PIK3CA GPC3 HNF1B ARID1A KRAS TP53
4 endocrine/exocrine gland MP:0005379 10 KRAS CD44 PIK3CA HNF1B ARID1A TP53
5 immune system MP:0005387 9.97 KRAS CD44 PIK3CA GPC3 HNF1B ARID1A
6 muscle MP:0005369 9.87 CD44 PIK3CA HNF1B ARID1A KRAS TP53
7 neoplasm MP:0002006 9.8 PIK3CA PPP2R1A ARID1A KRAS CD44 TP53
8 renal/urinary system MP:0005367 9.7 CD44 KRT7 GPC3 HNF1B KRAS TP53
9 reproductive system MP:0005389 9.5 KRAS CD44 PIK3CA GPC3 ARID1A TP53
10 skeleton MP:0005390 9.17 KRAS CD44 PIK3CA GPC3 ARID1A TP53

Drugs & Therapeutics for Ovarian Clear Cell Carcinoma

Drugs for Ovarian Clear Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
2
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
3
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
4
Nintedanib Approved Phase 2 656247-17-5 56843413
5
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
6
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
7
Bevacizumab Approved, Investigational Phase 2 216974-75-3
8
nivolumab Approved Phase 2 946414-94-4
9
Doxil Approved June 1999 Phase 2 31703
10 Angiogenesis Inhibitors Phase 2
11 Angiogenesis Modulating Agents Phase 2
12 Albumin-Bound Paclitaxel Phase 2
13 Anti-Bacterial Agents Phase 2
14 Antibiotics, Antitubercular Phase 2
15 Antimitotic Agents Phase 2
16 Antineoplastic Agents, Phytogenic Phase 2
17 topoisomerase I inhibitors Phase 2
18 Topoisomerase Inhibitors Phase 2
19 Antibodies Phase 2,Phase 1
20 Antibodies, Monoclonal Phase 2
21 Immunoglobulins Phase 2,Phase 1
22 tyrosine Nutraceutical Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
2 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
3 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
4 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
5 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
6 A Study of PLX2853 in Advanced Malignancies. Recruiting NCT03297424 Phase 1, Phase 2 PLX2853
7 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Active, not recruiting NCT02837991 Phase 1 CDX-014

Search NIH Clinical Center for Ovarian Clear Cell Carcinoma

Genetic Tests for Ovarian Clear Cell Carcinoma

Anatomical Context for Ovarian Clear Cell Carcinoma

MalaCards organs/tissues related to Ovarian Clear Cell Carcinoma:

41
Ovary, Lymph Node, Monocytes, Cervix

Publications for Ovarian Clear Cell Carcinoma

Articles related to Ovarian Clear Cell Carcinoma:

(show top 50) (show all 192)
# Title Authors Year
1
Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. ( 29751993 )
2018
2
Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. ( 29629954 )
2018
3
Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma. ( 29781825 )
2018
4
Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma. ( 29400012 )
2018
5
The HNF-1I^-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma. ( 29707125 )
2018
6
Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. ( 29044863 )
2018
7
The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours. ( 29464073 )
2018
8
ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death. ( 29247567 )
2018
9
Benign mesothelial nodules reflux within acquired cutaneous lymphangiectasia associated with huge ovarian clear cell carcinoma. ( 29222819 )
2018
10
Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma. ( 29725737 )
2018
11
Uncommon Human Telomerase Reverse Transcriptase Promoter Mutations Are Associated With Poor Survival in Ovarian Clear Cell Carcinoma. ( 29474637 )
2018
12
Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. ( 29675093 )
2018
13
Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute. ( 29941051 )
2018
14
PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. ( 29632642 )
2018
15
Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma. ( 29963273 )
2018
16
Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma. ( 29679177 )
2018
17
Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. ( 29663364 )
2018
18
Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma? ( 29383437 )
2018
19
ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. ( 29890703 )
2018
20
Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. ( 29233531 )
2018
21
Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma. ( 29685880 )
2018
22
Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma. ( 29749539 )
2018
23
Imaging in gynecological disease: clinical and ultrasound characteristics of ovarian clear cell carcinoma. ( 29978567 )
2018
24
MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma. ( 28161486 )
2017
25
Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. ( 27939411 )
2017
26
Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma. ( 28930811 )
2017
27
Safety of fertility-sparing surgery for stage I ovarian clear cell carcinoma. ( 29027405 )
2017
28
UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan. ( 28173214 )
2017
29
Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression. ( 27873496 )
2017
30
Identification of LEFTY as a molecular marker for ovarian clear cell carcinoma. ( 28969018 )
2017
31
Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties. ( 28112360 )
2017
32
Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. ( 28187748 )
2017
33
The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma<i>In Vitro</i>and<i>In Vivo</i>. ( 29061793 )
2017
34
Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma? ( 28758377 )
2017
35
Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma inA vitro. ( 28259988 )
2017
36
Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma. ( 29285368 )
2017
37
Ovarian clear cell carcinoma with plasma cell-rich inflammatory stroma: Cytological Findings of a Case. ( 27718331 )
2017
38
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. ( 28920005 )
2017
39
[Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma]. ( 29325268 )
2017
40
Syndrome of inappropriate antidiuretic hormone secretion following irinotecan-cisplatin administration as a treatment for recurrent ovarian clear cell carcinoma. ( 28217682 )
2017
41
NOVEL POTENTIAL PHOTODYNAMIC THERAPY STRATEGY USING 5-AMINOLEVULINIC ACID FOR OVARIAN CLEAR-CELL CARCINOMA. ( 29196245 )
2017
42
Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. ( 28888422 )
2017
43
Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma. ( 28611940 )
2017
44
Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma. ( 28646535 )
2017
45
Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma. ( 28438620 )
2017
46
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. ( 29027395 )
2017
47
The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma. ( 29019869 )
2017
48
Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma. ( 28796747 )
2017
49
Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. ( 28728166 )
2017
50
Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma? ( 28760368 )
2017

Variations for Ovarian Clear Cell Carcinoma

Cosmic variations for Ovarian Clear Cell Carcinoma:

9
(show top 50) (show all 230)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6947228 ZFHX3 ovary,NS,carcinoma,clear cell carcinoma c.3472G>A p.G1158R 16:72829836-72829836 9
2 COSM11606 TP53 ovary,NS,carcinoma,clear cell carcinoma c.31G>C p.E11Q 17:7676564-7676564 9
3 COSM10738 TP53 ovary,NS,carcinoma,clear cell carcinoma c.542G>A p.R181H 17:7675070-7675070 9
4 COSM11123 TP53 ovary,NS,carcinoma,clear cell carcinoma c.838A>G p.R280G 17:7673782-7673782 9
5 COSM10663 TP53 ovary,NS,carcinoma,clear cell carcinoma c.916C>T p.R306* 17:7673704-7673704 9
6 COSM10667 TP53 ovary,NS,carcinoma,clear cell carcinoma c.646G>A p.V216M 17:7674885-7674885 9
7 COSM44923 TP53 ovary,NS,carcinoma,clear cell carcinoma c.565G>C p.A189P 17:7674966-7674966 9
8 COSM43896 TP53 ovary,NS,carcinoma,clear cell carcinoma c.818G>C p.R273P 17:7673802-7673802 9
9 COSM10725 TP53 ovary,NS,carcinoma,clear cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 9
10 COSM10648 TP53 ovary,NS,carcinoma,clear cell carcinoma c.524G>A p.R175H 17:7675088-7675088 9
11 COSM43697 TP53 ovary,NS,carcinoma,clear cell carcinoma c.832C>A p.P278T 17:7673788-7673788 9
12 COSM10704 TP53 ovary,NS,carcinoma,clear cell carcinoma c.844C>T p.R282W 17:7673776-7673776 9
13 COSM6071317 TBX3 ovary,NS,carcinoma,clear cell carcinoma c.307C>A p.P103T 12:114682894-114682894 9
14 COSM20625 STK3 ovary,NS,carcinoma,clear cell carcinoma c.178G>C p.V60L 8:98767301-98767301 9
15 COSM21355 STK11 ovary,NS,carcinoma,clear cell carcinoma c.842C>T p.P281L 19:1221320-1221320 9
16 COSM6966368 STAT3 ovary,NS,carcinoma,clear cell carcinoma c.271C>T p.Q91* 17:42346571-42346571 9
17 COSM6926931 STAT3 ovary,NS,carcinoma,clear cell carcinoma c.1907C>T p.S636F 17:42322476-42322476 9
18 COSM6974933 STAT3 ovary,NS,carcinoma,clear cell carcinoma c.1238T>G p.L413R 17:42329453-42329453 9
19 COSM980818 SPOP ovary,NS,carcinoma,clear cell carcinoma c.148G>A p.E50K 17:49621998-49621998 9
20 COSM6904351 SPOP ovary,NS,carcinoma,clear cell carcinoma c.235G>A p.E79K 17:49619351-49619351 9
21 COSM88679 SPOP ovary,NS,carcinoma,clear cell carcinoma c.139G>A p.E47K 17:49622007-49622007 9
22 COSM6973364 SOX9 ovary,NS,carcinoma,clear cell carcinoma c.92C>G p.A31G 17:72121483-72121483 9
23 COSM6919565 SOX9 ovary,NS,carcinoma,clear cell carcinoma c.604G>A p.A202T 17:72122891-72122891 9
24 COSM6019342 SMARCA4 ovary,NS,carcinoma,clear cell carcinoma c.467G>T p.G156V 19:10986300-10986300 9
25 COSM255312 SMARCA4 ovary,NS,carcinoma,clear cell carcinoma c.3727C>T p.R1243W 19:11033470-11033470 9
26 COSM6926933 SMARCA4 ovary,NS,carcinoma,clear cell carcinoma c.3564C>A p.D1188E 19:11033307-11033307 9
27 COSM14146 SMAD4 ovary,NS,carcinoma,clear cell carcinoma c.1135G>A p.A379T 18:51065602-51065602 9
28 COSM6947226 SMAD3 ovary,NS,carcinoma,clear cell carcinoma c.1136G>T p.G379V 15:67187491-67187491 9
29 COSM132950 SF3B1 ovary,NS,carcinoma,clear cell carcinoma c.1996A>C p.K666Q 2:197402637-197402637 9
30 COSM6931475 RPTOR ovary,NS,carcinoma,clear cell carcinoma c.3365C>T p.T1122M 17:80949542-80949542 9
31 COSM6917539 RNF43 ovary,NS,carcinoma,clear cell carcinoma c.702G>C p.Q234H 17:58360930-58360930 9
32 COSM6981024 RICTOR ovary,NS,carcinoma,clear cell carcinoma c.449T>C p.V150A 5:38996826-38996826 9
33 COSM241316 PTPRT ovary,NS,carcinoma,clear cell carcinoma c.2162G>A p.R721H 20:42282503-42282503 9
34 COSM6923181 PTPRD ovary,NS,carcinoma,clear cell carcinoma c.5279C>A p.A1760E 9:8339022-8339022 9
35 COSM5219 PTEN ovary,NS,carcinoma,clear cell carcinoma c.388C>G p.R130G 10:87933147-87933147 9
36 COSM5036 PTEN ovary,NS,carcinoma,clear cell carcinoma c.202T>C p.Y68H 10:87925550-87925550 9
37 COSM5089 PTEN ovary,NS,carcinoma,clear cell carcinoma c.517C>T p.R173C 10:87952142-87952142 9
38 COSM23650 PTEN ovary,NS,carcinoma,clear cell carcinoma c.728T>C p.F243S 10:87957946-87957946 9
39 COSM6019341 PTCH1 ovary,NS,carcinoma,clear cell carcinoma c.3073C>T p.R1025C 9:95458108-95458108 9
40 COSM51211 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.547C>T p.R183W 19:52212729-52212729 9
41 COSM51253 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.548G>A p.R183Q 19:52212730-52212730 9
42 COSM76040 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.771G>T p.W257C 19:52213074-52213074 9
43 COSM86040 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.772C>T p.R258C 19:52213075-52213075 9
44 COSM51210 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.547C>G p.R183G 19:52212729-52212729 9
45 COSM51212 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.544C>T p.R182W 19:52212726-52212726 9
46 COSM6917537 POLE ovary,NS,carcinoma,clear cell carcinoma c.1124G>A p.R375Q 12:132675500-132675500 9
47 COSM6919564 PLK2 ovary,NS,carcinoma,clear cell carcinoma c.344A>T p.H115L 5:58459019-58459019 9
48 COSM6981028 PLCG2 ovary,NS,carcinoma,clear cell carcinoma c.2200C>T p.P734S 16:81919629-81919629 9
49 COSM775 PIK3CA ovary,NS,carcinoma,clear cell carcinoma c.3140A>G p.H1047R 3:179234297-179234297 9
50 COSM12458 PIK3CA ovary,NS,carcinoma,clear cell carcinoma c.1634A>C p.E545A 3:179218304-179218304 9

Copy number variations for Ovarian Clear Cell Carcinoma from CNVD:

7 (show top 50) (show all 427)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13831 1 1 88452 Loss Ovarian clear cell carcinoma
2 14094 1 103933871 104104913 Loss Ovarian clear cell carcinoma
3 14228 1 105814888 105835737 Loss Ovarian clear cell carcinoma
4 14767 1 110029012 110047636 Gain Ovarian clear cell carcinoma
5 14768 1 110029027 110046508 Loss Ovarian clear cell carcinoma
6 15067 1 112489835 112507466 Gain Ovarian clear cell carcinoma
7 15068 1 112491838 112507466 Loss Ovarian clear cell carcinoma
8 18079 1 143856437 146851948 Gain Ovarian clear cell carcinoma
9 18686 1 147137550 147788457 Gain Ovarian clear cell carcinoma
10 18898 1 147703455 147884062 Loss Ovarian clear cell carcinoma
11 18938 1 147964875 159663147 Gain Ovarian clear cell carcinoma
12 18939 1 147964875 159663147 Gain Ovarian clear cell carcinoma
13 19585 1 150821801 150857105 Loss Ovarian clear cell carcinoma
14 19705 1 151026303 151040528 Loss Ovarian clear cell carcinoma
15 21673 1 16022491 16026775 Gain Ovarian clear cell carcinoma
16 21674 1 16024203 16038247 Loss Ovarian clear cell carcinoma
17 22558 1 167482724 167509012 Loss Ovarian clear cell carcinoma
18 22559 1 167482724 167521488 Gain Ovarian clear cell carcinoma
19 22780 1 16889448 16921459 Gain Ovarian clear cell carcinoma
20 24231 1 177344731 177346824 Loss Ovarian clear cell carcinoma
21 24465 1 180956979 181720785 Gain Ovarian clear cell carcinoma
22 25838 1 194981485 195068682 Gain Ovarian clear cell carcinoma
23 25839 1 194981485 195083340 Loss Ovarian clear cell carcinoma
24 26133 1 197378133 197380848 Loss Ovarian clear cell carcinoma
25 26790 1 202780704 202781223 Loss Ovarian clear cell carcinoma
26 27522 1 209500000 222100000 Amplification CENPF Ovarian clear cell carcinoma
27 28170 1 219471 557615 Gain Ovarian clear cell carcinoma
28 28576 1 223563323 234670833 Gain Ovarian clear cell carcinoma
29 29195 1 228800000 234600000 Amplification TARBP1 Ovarian clear cell carcinoma
30 29315 1 230223390 230231832 Loss Ovarian clear cell carcinoma
31 29845 1 236917532 236921700 Loss Ovarian clear cell carcinoma
32 29954 1 238458352 238460749 Loss Ovarian clear cell carcinoma
33 30919 1 246707804 246877268 Gain Ovarian clear cell carcinoma
34 30947 1 246804059 246863823 Loss Ovarian clear cell carcinoma
35 31115 1 25455917 25517758 Gain Ovarian clear cell carcinoma
36 31116 1 25455917 25534075 Loss Ovarian clear cell carcinoma
37 32697 1 38901189 38907774 Gain Ovarian clear cell carcinoma
38 36176 1 72522942 72600553 Loss Ovarian clear cell carcinoma
39 36192 1 72535947 72584491 Gain Ovarian clear cell carcinoma
40 37128 1 85775755 85782373 Loss Ovarian clear cell carcinoma
41 37531 1 92007142 92023072 Loss Ovarian clear cell carcinoma
42 39168 10 11150202 11151804 Loss Ovarian clear cell carcinoma
43 41309 10 15959139 15974926 Loss Ovarian clear cell carcinoma
44 41503 10 19683194 19835050 Loss Ovarian clear cell carcinoma
45 41826 10 24415258 24418944 Gain Ovarian clear cell carcinoma
46 41827 10 24415258 24420691 Loss Ovarian clear cell carcinoma
47 42276 10 31286505 31291815 Loss Ovarian clear cell carcinoma
48 42716 10 3813637 3819468 Gain Ovarian clear cell carcinoma
49 42973 10 4276898 4287271 Gain Ovarian clear cell carcinoma
50 43007 10 42910287 42910797 Gain Ovarian clear cell carcinoma

Expression for Ovarian Clear Cell Carcinoma

Search GEO for disease gene expression data for Ovarian Clear Cell Carcinoma.

Pathways for Ovarian Clear Cell Carcinoma

Pathways related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 KRAS PIK3CA PPP2R1A PTEN TP53
2
Show member pathways
12.62 KRAS PIK3CA PTEN TP53
3
Show member pathways
12.6 ARID1A KRAS PIK3CA PTEN TP53
4
Show member pathways
12.56 KRAS PIK3CA PTEN TP53
5
Show member pathways
12.56 KRAS PIK3CA PPP2R1A PTEN TP53
6
Show member pathways
12.41 KRAS PIK3CA PTEN TP53
7
Show member pathways
12.26 CD44 GPC3 KRAS PIK3CA
8 12.24 CD44 KRAS PIK3CA PTEN TP53
9
Show member pathways
12.18 GPC3 KRAS PIK3CA PTEN TP53
10
Show member pathways
12.03 KRAS PIK3CA TP53
11 12.02 KRAS PIK3CA PTEN TP53
12 12.01 KRAS PTEN TP53
13 12.01 KRAS PIK3CA PTEN TP53
14
Show member pathways
11.99 KRAS PIK3CA PTEN
15
Show member pathways
11.99 KRAS PIK3CA TP53
16 11.96 CD44 GPC3 KRAS PIK3CA TP53
17
Show member pathways
11.94 KRAS PIK3CA PTEN
18 11.9 KRAS PIK3CA PTEN
19 11.9 KRAS PIK3CA PPP2R1A TP53
20
Show member pathways
11.89 PIK3CA PTEN TP53
21 11.83 KRAS PTEN TP53
22 11.8 CD44 PTEN TP53
23 11.8 FXYD2 KRAS PIK3CA TP53
24 11.77 KRAS PIK3CA PTEN TP53
25 11.72 PIK3CA PTEN TP53
26 11.46 PIK3CA PTEN TP53
27 11.28 ARID1A PIK3CA PTEN TP53
28 11.24 FXYD2 KRAS PIK3CA
29 11.11 KRAS PIK3CA PTEN
30 11.09 KRAS PIK3CA PPP2R1A PTEN TP53
31 11.07 KRAS PIK3CA PTEN TP53

GO Terms for Ovarian Clear Cell Carcinoma

Biological processes related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.46 HNF1B KRAS PTEN TP53
2 regulation of synaptic transmission, GABAergic GO:0032228 8.96 KRAS PTEN
3 liver development GO:0001889 8.8 HNF1B KRAS PIK3CA

Sources for Ovarian Clear Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....